European Neuropsychopharmacology
Volume 20, Issue 7 , Pages 433-453 , July 2010

Antidepressants in healthy subjects: What are the psychotropic/psychological effects?

  • Alessandro Serretti

      Affiliations

    • Institute of Psychiatry, University of Bologna, Italy
    • Corresponding Author InformationCorresponding author. Institute of Psychiatry, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy. Tel.: +39 051 6584233; fax: +39 051 521030.
    • ,
  • Raffaella Calati

      Affiliations

    • Institute of Psychiatry, University of Bologna, Italy
    • ,
  • Arianna Goracci

      Affiliations

    • Department of Neurosciences, Psychiatry Unit, University of Siena, Italy
    • ,
  • Martina Di Simplicio

      Affiliations

    • Department of Neurosciences, Psychiatry Unit, University of Siena, Italy
    • ,
  • Paolo Castrogiovanni

      Affiliations

    • Department of Neurosciences, Psychiatry Unit, University of Siena, Italy
    • ,
  • Diana De Ronchi

      Affiliations

    • Institute of Psychiatry, University of Bologna, Italy

Received 22 April 2009 ,Revised 12 November 2009 ,Accepted 22 November 2009.

References 

  1. Anderson IM, Del-Ben CM, McKie S, Richardson P, Williams SR, Elliott R, et al. Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. NeuroReport. 2007;18:1351–1355
  2. Andrews W, Parker G, Barrett E. The SSRI antidepressants: exploring their “other” possible properties. J. Affect. Disord. 1998;49:141–144
  3. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl). 2008;196:661–672
  4. Arnone D, Horder J, Cowen PJ, Harmer CJ. Early effects of mirtazapine on emotional processing. Psychopharmacology (Berl). 2009;203:685–691
  5. Bailey JE, Kendrick A, Diaper A, Potokar JP, Nutt DJ. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J. Psychopharmacol. 2007;21:42–49
  6. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J. Psychiatr. Pract. 2004;10:196–199
  7. Barondes SH. Thinking about Prozac. Nature. 1994;363:1102–1103
  8. Benedetti F, Bernasconi A, Blasi V, Cadioli M, Colombo C, Falini A, et al. Neural and genetic correlates of antidepressant response to sleep deprivation: a functional magnetic resonance imaging study of moral valence decision in bipolar depression. Arch. Gen. Psychiatry. 2007;64:179–187
  9. Besnier N, Casse-Perrot C, Jouve E, Nguyen N, Lancon C, Falissard B, et al. Effects of paroxetine on emotional functioning and treatment awareness: a 4-week randomized placebo-controlled study in healthy clinicians. Psychopharma- cology (Berl). 2010;207:619–629
  10. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology. 2008;33:3221–3225
  11. Boz C, Gazioglu S, Altunayoglu V, Hocaoglu C. Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache. Psychiatry Clin. Neurosci. 2007;61:534–542
  12. Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer C. A single dose of citalopram increases fear recognition in healthy subjects. J. Psychopharmacol. 2007;21:684–690
  13. Buckholtz JW, Callicott JH, Kolachana B, Hariri AR, Goldberg TE, Genderson M, et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol. Psychiatry. 2008;13:313–324
  14. Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol. Psychiatry. 2004;55:1171–1178
  15. Carvalho AF, Kohler CA, Cruz EP, Sturmer PL, Reichman BP, Barea BM, et al. Acute treatment with the antidepressants bupropion and sertraline do not influence memory retrieval in man. Eur. Arch. Psychiatry Clin. Neurosci. 2006;256:320–325
  16. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006;311:861–863
  17. Cools R, Roberts AC, Robbins TW. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn. Sci. 2008;12:31–40
  18. de Bruijn ER, Hulstijn W, Verkes RJ, Ruigt GS, Sabbe BG. Drug-induced stimulation and suppression of action monitoring in healthy volunteers. Psychopharmacology (Berl). 2004;177:151–160
  19. de Bruijn ER, Sabbe BG, Hulstijn W, Ruigt GS, Verkes RJ. Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers. Brain Res. 2006;1105:122–129
  20. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology. 2005;30:1724–1734
  21. Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. Psychopharmacology (Berl). 1992;106 Suppl:S68–S70
  22. Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch. Gen. Psychiatry. 2006;63:1396–1406
  23. Fairweather DB, Ashford J, Hindmarch I. Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Pharmacol. Biochem. Behav. 1996;53:265–269
  24. Freeman H. Listening to Prozac—correspondence. Nature. 1994;369:178
  25. Furlan PM, Kallan MJ, Have TT, Lucki I, Katz I. SSRIs do not cause affective blunting in healthy elderly volunteers. Am. J. Geriatr. Psychiatry. 2004;12:323–330
  26. Gelfin Y, Gorfine M, Lerer B. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am. J. Psychiatry. 1998;155:290–292
  27. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry. 2005;62:146–152
  28. Harmer CJ. Serotonin and emotional processing: does it help explain antidepressant drug action?. Neuropharmacology. 2008;55:1023–1028
  29. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28:148–152
  30. Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am. J. Psychiatry. 2003;160:990–992
  31. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry. 2004;161:1256–1263
  32. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry. 2006;59:816–820
  33. Harmer CJ, Heinzen J, O'Sullivan U, Ayres RA, Cowen PJ. Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers. Psychopharmacology (Berl). 2008;199:495–502
  34. Iwamoto K, Kawamura Y, Takahashi M, Uchiyama Y, Ebe K, Yoshida K, et al. Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers. Psychiatry Clin. Neurosci. 2008;62:610–616
  35. Iwamoto K, Takahashi M, Nakamura Y, Kawamura Y, Ishihara R, Uchiyama Y, et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum. Psychopharmacol. 2008;23:399–407
  36. Kellner M, Demiralay C, Muhtz C, Husemann J, Kolsch W, Hiemke C, et al. No effect of six weeks of treatment with escitalopram on mood in healthy volunteers—irrespective of genotype for the promoter of the serotonin transporter. Psychiatry Res. 2008;161:339–343
  37. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am. J. Psychiatry. 1998;155:373–379
  38. Kramer PD. Listening to Prozac. A psychiatrist explores antidepressant drugs and the remaking of the self. New York: Viking; 1993;
  39. Li H, Yuan J, Lin C. The neural mechanism underlying the female advantage in identifying negative emotions: an event-related potential study. Neuroimage. 2008;40:1921–1929
  40. Mattila M, Mattila MJ, Vrijmoed-de Vries M, Kuitunen T. Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol. Toxicol. 1989;65:81–88
  41. Medawar C. Through the doors of deception?. Nature. 1994;368:369–370
  42. Miskowiak K, Papadatou-Pastou M, Cowen PJ, Goodwin GM, Norbury R, Harmer CJ. Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. Neuroimage. 2007;37:904–911
  43. Mitchell PJ, Redfern PH. Chronic treatment with clomipramine and mianserin increases the hierarchical position of subdominant rats housed in triads. Behav. Pharmacol. 1992;3:239–247
  44. Mitchell PJ, Fletcher A, Redfern PH. Is antidepressant efficacy revealed by drug-induced changes in rat behaviour exhibited during social interaction?. Neurosci. Biobehav. Rev. 1991;15:539–544
  45. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br. J. Psychiatry. 2007;190:531–532
  46. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol. Psychiatry. 2007;13:1011–1020
  47. Paul MA, Gray GW, Love RJ, Lange M. SSRI effects on pyschomotor performance: assessment of citalopram and escitalopram on normal subjects. Aviat. Space Environ. Med. 2007;78:693–697
  48. Quitkin FM. Placebos, drug effects, and study design: a clinician's guide. Am. J. Psychiatry. 1999;156:829–836
  49. Ridout F, Meadows R, Johnsen S, Hindmarch I. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum. Psychopharmacol. 2003;18:261–269
  50. Riedel WJ, Eikmans K, Heldens A, Schmitt JA. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J. Psychopharmacol. 2005;19:12–20
  51. Rosenzweig P, Patat A, Zieleniuk I, Cimarosti I, Allain H, Gandon JM. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor. Clin. Pharmacol. Ther. 1998;64:211–222
  52. Semlitsch HV, Anderer P, Saletu B, Binder GA, Decker KA. Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjects. Int. Clin. Psychopharmacol. 1993;8:155–166
  53. Settle EC. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J. Clin. Psychiatry. 1998;59(Suppl 16):25–30discussion 40-2
  54. Siepmann M, Grossmann J, Muck-Weymann M, Kirch W. Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl). 2003;168:293–298
  55. Siepmann M, Handel J, Mueck-Weymann M, Kirch W. The effects of moclobemide on autonomic and cognitive functions in healthy volunteers. Pharmacopsychiatry. 2004;37:81–87
  56. Siepmann T, Mueck-Weymann M, Oertel R, Kirch W, Pittrow D, Siepmann M. The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. Pharmacopsychiatry. 2008;41:146–150
  57. Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br. J. Psychiatry. 2009;194:483–490
  58. Sullivan S, Ruffman T. Emotion recognition deficits in the elderly. Int. J. Neurosci. 2004;114:403–432
  59. Takahashi H, Yahata N, Koeda M, Takano A, Asai K, Suhara T, et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage. 2005;27:991–1001
  60. Tse WS, Bond AJ. Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berl). 2002;159:216–221
  61. Tse WS, Bond AJ. Serotonergic intervention affects both social dominance and affiliative behaviour. Psychopharmacology (Berl). 2002;161:324–330
  62. Tse WS, Bond AJ. Reboxetine promotes social bonding in healthy volunteers. J. Psychopharmacol. 2003;17:189–195
  63. Tse WS, Bond AJ. Noradrenaline might enhance assertive human social behaviours: an investigation in a flatmate relationship. Pharmacopsychiatry. 2006;39:175–179
  64. van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J. Clin. Psychopharmacol. 1995;15:30–40
  65. Vollm B, Richardson P, McKie S, Elliott R, Deakin JF, Anderson IM. Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. Eur. J. NeuroSci. 2006;23:552–560
  66. Warot D, Berlin I, Patat A, Durrieu G, Zieleniuk I, Puech AJ. Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects. J. Clin. Pharmacol. 1996;36:942–950
  67. Wezenberg E, Sabbe BG, Hulstijn W, Ruigt GS, Verkes RJ. The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. J. Psychopharmacol. 2007;21:579–587
  68. Wilson SJ, Bailey JE, Alford C, Weinstein A, Nutt DJ. Effects of 5weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J. Psychopharmacol. 2002;16:321–331
  69. Wingen M, Kuypers KP, van de Ven V, Formisano E, Ramaekers JG. Sustained attention and serotonin: a pharmaco-fMRI study. Hum. Psychopharmacol. 2008;23:221–230
  70. Wong WM, Hasemann S, Schwarz M, Zill P, Koller G, Soyka M, et al. Citalopram neuropharmacological challenge in alcohol-dependent patients and controls: pharmacogenetic, endocrine and psychobehavioral results. Pharmacopsychiatry. 2008;41:72–78
  71. Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann. Gen. Psychiatry. 2007;6:7

PII: S0924-977X(09)00260-0

doi: 10.1016/j.euroneuro.2009.11.009

European Neuropsychopharmacology
Volume 20, Issue 7 , Pages 433-453 , July 2010

Article Tools

* Image Usage & Resolution